Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

. 2015 Mar;8(Spec Feature):96-100.

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Lisa A Raedler

PMID: 26629272
PMCID: PMC4665064

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Lisa A Raedler. Am Health Drug Benefits. 2015 Mar.

. 2015 Mar;8(Spec Feature):96-100.

Author

Lisa A Raedler

PMID: 26629272
PMCID: PMC4665064

No abstract available

PubMed Disclaimer

Cited by

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, Uyl-de Groot CA. Heine RJSD, et al. PLoS One. 2024 Feb 1;19(2):e0293264. doi: 10.1371/journal.pone.0293264. eCollection 2024. PLoS One. 2024. PMID: 38300937 Free PMC article.
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity.
Wright QG, Sinha D, Wells JW, Frazer IH, Gonzalez Cruz JL, Leggatt GR. Wright QG, et al. J Immunother Cancer. 2024 Jan 31;12(1):e007960. doi: 10.1136/jitc-2023-007960. J Immunother Cancer. 2024. PMID: 38296598 Free PMC article.
Exploring Pembrolizumab-Induced Myocarditis, Myositis, and Myasthenia Gravis: A Comprehensive Literature Review and Case Presentation on Bladder Cancer.
Shah D, Young K. Shah D, et al. Cureus. 2023 Dec 3;15(12):e49867. doi: 10.7759/cureus.49867. eCollection 2023 Dec. Cureus. 2023. PMID: 38169986 Free PMC article.
Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I, Reneau JC, Hanel W, Chung CG. Quadri I, et al. Front Immunol. 2023 Nov 3;14:1291259. doi: 10.3389/fimmu.2023.1291259. eCollection 2023. Front Immunol. 2023. PMID: 38022633 Free PMC article. Review.
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance.
Mamat Yusof MN, Chew KT, Kampan NC, Shafiee MN. Mamat Yusof MN, et al. Int J Mol Sci. 2023 Oct 16;24(20):15233. doi: 10.3390/ijms242015233. Int J Mol Sci. 2023. PMID: 37894913 Free PMC article. Review.

See all "Cited by" articles

References

1. Skin Cancer Foundation. Melanoma. www.skincancer.org/skin-cancer-information/melanoma. Accessed October 17, 2014.
1. National Cancer Institute. SEER stat fact sheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html. Accessed October 17, 2014.
1. Reed KB, Brewer JD, Lohse CM, et al. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012; 87:328–334. - PMC - PubMed
1. Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973–2009. Pediatrics. 2013; 131:846–854. - PMC - PubMed
1. Davis KL, Mitra D, Kotapati S, et al. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy. 2009; 7:31–41. - PubMed

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- The Lens - Patent Citations

[1] Skin Cancer Foundation. Melanoma. www.skincancer.org/skin-cancer-information/melanoma. Accessed October 17, 2014.

[2] Skin Cancer Foundation. Melanoma. www.skincancer.org/skin-cancer-information/melanoma. Accessed October 17, 2014.

[3] National Cancer Institute. SEER stat fact sheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html. Accessed October 17, 2014.

[4] National Cancer Institute. SEER stat fact sheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html. Accessed October 17, 2014.

[5] Reed KB, Brewer JD, Lohse CM, et al. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012; 87:328–334. - PMC - PubMed

[6] Reed KB, Brewer JD, Lohse CM, et al. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012; 87:328–334. - PMC - PubMed

[7] Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973–2009. Pediatrics. 2013; 131:846–854. - PMC - PubMed

[8] Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973–2009. Pediatrics. 2013; 131:846–854. - PMC - PubMed

[9] Davis KL, Mitra D, Kotapati S, et al. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy. 2009; 7:31–41. - PubMed

[10] Davis KL, Mitra D, Kotapati S, et al. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy. 2009; 7:31–41. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Author

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources